Early studies have cast doubt on the utility of animal models for predicting success or failure of HIV-prevention strategies, but results of multiple human phase 3 microbicide trials, and interrogations into the discrepancies between human and animal model trials, indicate that animal models were, and are, predictive of safety and efficacy of microbicide candidates.
INTRODUCTION
Animal models are indispensible for preclinical testing of HIV-prevention strategies. Advances in understanding the female reproductive tract, the early events in vaginal HIV transmission, and a better understanding and appreciation of the similarities and differences in animal models are finally converging to provide a well tolerated and effective path to topical microbicide development. Although we have made some success with antiretroviral pre-exposure prophylaxis (PreP), we are a long way from licensing an inexpensive, topical microbicide that will actually have an impact on HIV transmission in endemic countries. Continued research in determining the early immune responses in human mucosal tissues responsible for HIV transmission is essential to this development, as topical applications of substances previously tested for safety in vitro, and sometimes even FDA-approved for use in mucosal tissues, resulted in mucosal irritation and recruitment of target cells after repeated use, and actually increased rates of HIV-1 transmission.
We now know that the early, innate immune response, characterized by a cytokine storm and recruitment of additional CD4 þ T cells and antigen-presenting cells, actually fuels early HIV replication in mucosal tissues [ ]. Therefore, we will focus this review primarily on the utility, relevance, and appropriate use of specific animal models for vaginal microbicide testing, which has evolved in parallel with our expanding knowledge of the early cellular and molecular events involved in vaginal HIV-1 transmission, which were in fact, mostly discovered in NHP models. Although rectal transmission is the focus of several ongoing microbicide investigations in macaques [10] [11] [12] , much less is known regarding the early events involved in rectal transmission, partly due to technical limitations of studying the gut, so we focus here on what is known regarding the early events involved in vaginal transmission. However, studies that have compared intestinal and vaginal immune cells and responses in humans [13] and macaques [14] suggest these mucosal tissues have at least some parallels, so we may extrapolate many of the same mucosal immunologic responses to rectal transmission.
Finally, we discuss some of the historical 'discrepancies' in animal models of HIV-prevention research, which in hindsight have consistently revealed the animal models were indeed predictive, but sometimes our assumptions, experimental designs, or even the data obtained from human clinical trials are misleading. This has been continuously illustrated by failed human clinical trials, most recently in the announcement of extremely poor compliance rates in the VOICE trial of oral and topical tenofovir in African women (http://www.mtnstopshiv.org/node/4877), which explained the discrepancies in efficacy between animal and human data for tenofovir gels. In the last 10 years, HIV-relevant animal models were usually considered an expensive and unnecessary step in advancing a compound to human trials, as FDA approval only required limited safety testing in less expensive models. Further, the lack of protective efficacy data for HIV prevention in humans meant there was nothing to which one could compare animal efficacy data. However, repeated failed human trials [3, [15] [16] [17] [18] revealed weaknesses in selection criteria, but also validated animal models as a necessary step in advancing future compounds to trials.
THE CRITICAL NEED FOR ANIMAL TESTING OF TOPICAL HIV-MICROBICIDE CANDIDATES
Perhaps no field of research more than the HIV microbicide field has demonstrated such a valid case for continued, and even expanded preclinical testing of microbicide candidates in animal models.
Despite showing safety and efficacy in a series of in-vitro assays, the first several topical microbicide trials in humans failed [10] , and at least one with disastrous consequences. One candidate (nonoxynol-9 or N-9) resulted in more HIV infections in the treatment groups compared with placebos [3] despite passing in-vitro screening assays [19] and even a single challenge trial in macaques (unpublished observations). In hindsight, it became evident that substances that attack HIV envelope also affect mucosal epithelial cells, as the HIV lipid envelope is derived from host cells [20] . Thus, repeated use of
KEY POINTS
Successful human trials of antiretrovirals administered as a topical mucosal gel, or as oral PrEP have shown efficacy in preventing HIV infections, which were originally predicted in animal models.
HIV-1 mucosal transmission may depend on inflammation, recruitment of target cells, and local expansion of the foci of infection for successful transmission, which cannot be duplicated in in-vitro models.
Repeated use of compounds that elicit mucosal inflammation, or repeated exposure to SIV/HIV alone may elicit mucosal inflammation, which must be considered in the design and safety testing of microbicides.
Microbicide testing in humanized mouse models of HIV-1 infection, and nonhuman primate models of SIV/SHIV transmission, are predictive of microbicide efficacy in humans, and should be used in preclinical microbicide safety and efficacy testing. detergents/surfactants (like N-9), or polyanions that damage cells, lipid bilayers, or substances that alter the mucosal environment all can result in irritation, local recruitment of viral target cells, and increased susceptibility to HIV transmission in vivo, which may not be predicted in cell or tissue culture models. However, this irritation could have been predicted, and subsequently has been demonstrated, in appro-
In other words, proper use of the model, by applying the compound as frequently as it would have been applied in human trials, or even a few times, would have predicted these failures. The problems were not with the model, but rather our limited understanding of the complex events required for successful HIV transmission, which were not taken into consideration at the time these tests were being conducted.
In-vitro systems lack the intact mucosal barrier system of a living animal model. The intact mucosa is comprised of several layers of epithelial cells, coated by a variably thick layer of mucus, containing antimicrobials and antibodies that likely affect HIV-1 transmission rates [21] . Further, the epithelial cells and resident dendritic cells coexpress a variety of receptors that trigger rapid immune responses from the underlying resident immunoregulatory cells, which then initiate dynamic cell to cell interactions resulting in a local cytokine storm, which elicits and recruits additional target cells from the bloodstream ( Fig. 1) 
Thus, even the most intricately designed in vitro models simply lack the potential for detecting inflammation elicited by repeated use of compounds, or exposure to virus. The complicated interactions of HIV with cervicovaginal mucus, vaginal epithelial integrity/ TLR receptor expression, resident T, NK, B cell and dendritic cell responses, changes in hormone levels, and recruitment of a myriad of inflammatory cells in response to microbicide or repeated HIV exposure make it even more critical that we utilize an animal model that recapitulates all of these events in humans as closely as possible, which makes the NHP model still the best model for vaginal microbicide testing (see below).
In summary, the vast and complex interactions of HIV with the multiple layers of the mucosal immune system cannot be mimicked in any meaningful way in any cell or tissue culture system in existence at this time. Similarly, these interactions cannot be reproduced in any relevant way by computer models or simulators, mainly because we simply lack the relevant data to plug into the transmission equations. For example, both vaginal and rectal HIV transmission is apparently highly inefficient, with a transmission rate estimated to be less than one in 900 vaginal exposures [22 & ]. As we do not know the reason(s) why mucosal transmission is so inefficient, and since relevant human samples simply cannot be obtained at the precise times needed to track successful HIV exposure/transmission, we may never prove the mucosal mechanisms involved in natural human HIV transmission. Further, and to counter the argument that animal models do not exactly mimic HIV transmissions in humans, it would be impossible to study these events in animal models as well, if transmission rates were just as low experimentally as they are in humans. Thus, relevant animal models for addressing specific questions of HIV-1 transmission, cyclic changes in vaginal susceptibility, or deciphering the predisposing factors essential for these rare transmission events, are critical for preclinical testing of effective microbicide or vaccine strategies.
Mice, sheep, goats, horses, cats, and so on, all have their own natural lentivirus infections that predominantly infect macrophages (a characteristic of lentiviruses) but none of these have the specific cell tropism to directly infect, and replicate in mucosal CD4 þ CCR5 þ T cells, which is an early, major feature of HIV infection in humans and SIV infection in susceptible nonhuman primate hosts. Further, we now know HIV and SIV infections occur as the result of infection with a single transmitted founder virus (TFV) which invariably uses CD4 and CCR5 for attachment and entry of host cells, and infected macrophages are not detected until weeks after viral exposure [23] [24] [25] . Thus, optimal models for HIV transmission should use TFV or at least R5 tropic HIV-1 or SIV/SHIVs for mucosal challenges. However, CD4 and CCR5 receptors in primates differ from those of lower animals, and only human and NHP cells are susceptible to infection with HIV-1. Therefore, for testing vaginal and rectal microbicides, we must either use genetically engineered, immunodeficient 'humanized' mouse models containing primary human fetal lymphoid tissue explants, which seed mucosal tissues with human immune cells and thus can be mucosally challenged with HIV-1, or else NHP models challenged with closely related SIV or SHIVs. Further, the list of available SHIVs with relevant HIV envelope proteins, and/or HIV reverse transcriptase (RT-SHIVs) continues to grow. As the envelope can be manipulated to express relevant HIV envelope proteins, while still maintaining a replication competent SIV backbone, these new SHIVs have added a new dimension of relevance to NHP models for mucosal prevention studies.
HUMANIZED MOUSE MODELS
In the last few years, there have been marked advances in the development of humanized murine models for HIV-1 research [9 && ]. The most frequently used and relevant models for HIV involve immunodeficient mice transplanted with human fetal cells and tissues to create 'humanized' mice that are susceptible to HIV-1 infection. The development and current availability of the different transgenic/humanized mouse models has recently been reviewed in detail [6 && ]. Basically, the most promising models used lack the ability to generate T and B cells (scid-hu), and/or nonobese diabetic (NOD) mice crossed with scid-humice, conferring additional defects that render NK cells dysfunctional, and/or further genetic mutations (Il2rg, Rag2, and so on) that render the murine host immune system even more defective, to prevent rejection of the human xenografts. These mice are then surgically implanted with human fetal tissue in an attempt to repopulate the murine immune system with human cells. For example, the 'BLT mouse' consists of a NOD/scid mouse transplanted with human fetal bone marrow, liver, and thymus (BLT) tissue [26] . This model is particularly encouraging for microbicide testing, as it is one of the few murine models in which mice can be persistently infected with HIV, and the engrafted human CD4 þ T cells appear to repopulate the mucosal tissues, which is especially relevant for HIV-prevention/ microbicide testing [27, 28] .
The advantage of such genetically altered and physically manipulated mice is obvious; we can use them to test actual HIV-1 strains, including TFH, and also, the virus is clearly infecting human cells, and not murine cells, thus removing any doubt regarding the relevance of the challenge virus or infected cells. Further, as the BLT model has human mucosal target cells, it is generally considered more relevant for mucosal challenge and microbicide screening [29 & ,30] . Thus, there are distinct advantages of using rodent models, especially for preliminary efficacy screening, as they are less expensive than NHP models, and they utilize HIV-1 and human cells for transmission. However, humanized mice lack key regulatory mechanisms involved in early innate immune responses, including interactions between intestinal and vaginal epithelial cells and the infiltrating human lymphocytes, the lack of an intestinal or vaginal microflora to interact with and respond to, and the co-dependence of specific cytokines and other associated inflammatory mediators generated from other cells that are likely mismatched in this model. Thus, the disadvantage of murine models is that their natural immune system may be so dramatically altered that it may complicate the early inflammatory cascade of events currently thought to be important for HIV transmission. Finally, there are major differences between the rodent and primate female reproductive tract including the absence of menstrual cycles in rodents (rodents have estrous cycles), which may be associated with differences in vaginal transmissibility. It is increasingly apparent that hormonal fluctuations associated with menstrual cycles and pregnancy, have dramatic effects on the local and systemic immune system [15] . Nonetheless, the development of humanized mouse models has accelerated the pace of microbicide screening. However, the interactions of HIV and mucosal innate immune responses needs to be further explored in this model, and recent studies have specifically been examining the mucosal immune responses and effects of microbicides in humanized mice to further validate these models [9 && ,29 & ,31].
Nonhuman primate models
Increasingly, it is clear early inflammatory responses in the cervix and vagina (Figs 1 and 2 ) play a key role in establishing infection. Thus, it is important to use a model that shares similarities in the structure and function of the human female reproductive tract (FRT), as well as one that recapitulates the early mucosal immune responses to viral exposure, as these are apparently fundamentally involved in transmission. The human FRT is a very dynamic system, with dramatic changes occurring in the vaginal epithelium, mucus production, microflora, pH, and immune responses, which in women, are all highly regulated by hormonal fluctuations [21] .
Most macaques have similar (yet variable -see [7 &
]) reproductive cycles as women, including menstrual cycles, which may periodically increase a woman's susceptibility to HIV transmission, which may prove relevant to sustained microbicide safety and efficacy testing in women. The role of hormones and associated risk factors on vaginal HIV transmission rates have been debated for decades, but a recent study in Africa demonstrated nearly a twofold increase in HIV acquisition rates in women taking injectable progestin-based contraceptives (Depo-Provera) [32] . This confirmed our observations made years ago in the NHP model, demonstrating that progesterone markedly increases vaginal transmission rates of SIV and SHIV in macaques [33] most likely due to thinning of the vaginal and ectocervical epithelium [12, 13] . As thinning of the vaginal epithelium may result in higher rates of transmission and increased local inflammation, we have been using this progesterone model as a more stringent test for the safety and efficacy of a microbicide [34] [35] [36] [37] [38] .
Vaginal epithelial thinning brings luminal foreign antigens/flora in closer proximity to underlying target cells in the vagina, which could result in direct HIV infection, or local inflammation, which may account for the increased susceptibility to HIV infection in women on contraceptives. However, hormonal influences associated with menstrual cycles, pregnancy, menopause, and so on, also affect the production of antimicrobials and/or early mucosal inflammatory responses to exposure, which could influence HIV transmission rates, and microbicide efficacy [21] . In support of this, studies of rhesus [39] and pigtail [40] macaques have shown that macaques are more susceptible to vaginal SIV/SHIV transmission during the luteal phase of the menstrual cycle, which could also have profound implications for HIV transmission to women. Further, we have found that the vaginal epithelium of pigtail macaques is less keratinized, and more similar to that of women than rhesus macaques, especially during menses (unpublished observations), which is likely why pigtails are more susceptible to multiple low-dose vaginal transmission of SIV/SHIV, and an excellent model for testing vaginal microbicides [7 & ,40]. Due to their close relation of NHP to humans, the similarity of the FRT, availability of tissues, and the ability to directly inoculate animals with specific pathogenic viruses, at precise times and doses of exposure, most of the major discoveries of vaginal and rectal HIV transmission, pathogenesis, immunology, among others have been made in NHP models, sometimes decades in advance of confirmation in humans. For example, the first successful trial of topical tenofovir gels for prevention of HIV-1 transmission in humans came from the Centre for the AIDS Program of Research in South Africa (CAPRISA 004) trial [41] which led to final FDA approval for use of oral tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) as a preexposure prophylaxis (PrEP) which was first predicted in the NHP model over 15 years ago by Tsai and Black et al. [42, 43] . Interestingly, now that additional human studies have continued to confirm the efficacy of oral tenofovir for prevention as PrEP [44] , and tenofovir in topical gels [41] , there has been a marked increase in animal testing of tenofovir to retrospectively validate the predictive nature of the models, and also, to more closely examine the tissue distribution and persistence (pharmacokinetics -PK) of drug delivery, and continued safety and efficacy with repeated use [11,12,31,45,46,47 && ]. Hopefully, now that successful human trials have finally been conducted, and once the animal models have been fully validated by these studies, NHP models will be better utilized to predict, rather than confirm human trials, which have their own limitations and complications. Moreover, continued research into safer and more reliable candidates and delivery methods for HIV prevention are needed, as toxicity, inflammation, emergence of resistant strains, and compliance are likely to emerge as major issues with the use of oral or topical antiretroviral drugs for PrEP.
Despite the success with tenofovir in human trials, new candidates are needed for topical microbicides, as long term or even intermittent PrEP may not be the safest approach to HIV prevention in uninfected populations. NHP models show that at least in higher doses, tenofovir has the potential for marked and permanent renal and toxicity, which may not be detectable in early stages with routine blood tests [48] . In addition, in a recent human trial, patients on oral tenofovir and emtricitabine reported significantly higher indications of toxicity including nausea, vomiting, and other concerning side-effects [49 && ]. Moreover, topical tenofovir results in marked local increases in CCL5 (RANTES) and TNF-a, both known promoters of cell recruitment and inflammation [24] . The latter should be a concern for vaginal and rectal applications, and poses the question of whether local tissue inflammation may occur in mucosal tissues with repeated dosing. For example, if repeated dosing results in inflammation, and subsequent doses are missed, could rates of HIV transmission actually increase in patients who are only partially compliant with topical antivirals? These are issues that should be seriously considered given the accumulating evidence of poor compliance with microbicide use in women. Finally, there is the potential for development of drug resistance with orally administered antiretrovirals, especially tenofovir, which frequently results in emergence of drug resistant strains of HIV/SIV. Thus, use of antivirals, either topically or systemically, could lead to resistance or increased rates of transmission in populations that have issues with compliance, which is why combination strategies and sustained delivery devices are critical for development of a well tolerated and effective topical microbicide.
Thus, the quest for safer, topical microbicides in sustained delivery systems is ongoing in animal models. In macaques, we have shown that topically applied microbicide gels or vaginal rings result in minimal uptake of drugs into the systemic circulation [50 & ,51 & ], mitigating any possible effects of systemic toxicity or viral resistance. Further, fusion inhibitors prevent cellular infection, which may also mitigate the inflammatory response compared FIGURE 2. Three color immunohistochemistry of the same animal in Fig 2b; infected for 10 days with simian immunodeficiency virus (SIV)mac. Note marked infiltration of CD3 þ T cells into the epithelium (green) and many are infected with SIV as shown by immunohistochemistry for p28 (gag -red). Macrophages (stained with mAbHam56) are shown in blue. Note all infected cells at this stage are T cells, and no infected macrophages are detected, consistent with infection from a CD4 þ CCR5 þ founder virus.
with a 'microbicide' that acts post entry, and permits infection and signaling of CD4 þ CCR5 þ T cells in tissues. Using the Depo-provera treated macaque model (a stringent model of safety and efficacy), we and others have shown that various fusion inhibitors including those that interfere either with gp120/CD4 binding [34,52,53 & ] or CCR5 attachment [36] [37] [38] 54, 55] can completely prevent vaginal SHIV transmission. Not only does this prove that molecular fusion inhibitors, which prevent infection of cells, may be effective as topical microbicides, it also tells us that CD4 and CCR5 binding are both essential for successful vaginal HIV-1 transmission, providing further clues to the mechanisms involved in HIV transmission. In addition, we have shown 'synergistic effects' in preventing vaginal SHIV transmission when using combinations of topical agents with different mechanisms of action [52] or when combining suboptimal doses of microbicides with partially effective vaccines [56 && ]. This vaccine/microbicide combination strategy is particularly attractive now, as vaccination could mitigate emerging compliance issues, and partially effective microbicides may be given more time to work in patients who are not 100% compliant. In summary, continued safety and efficacy testing of new candidates and concepts, combined with improved formulation and testing of delivery devices to overcome the major hurdles of human noncompliance, should continue, and accelerate in animal models.
THE UTILITY OF ANIMAL MODELS FOR PREDICTING HUMAN RESULTS
With respect to animal research, it has been said, 'mice lie, and monkeys exaggerate'. However, animal models actually do neither, as animal experiments simply provide scientific information that are subject to human interpretation, and are limited by the experimental design, which is often based on preconceived opinions. For example, the protection of macaques treated with N-9 and challenged once with SIV did not predict the failure and increased rates of HIV transmission demonstrated in humans who repeatedly used N-9. However, had the studies been designed the same way, the results in macaques would have been the same, as it has been subsequently shown that repeated mucosal N-9 applications in NHP also result in inflammation and tissue damage in animal models [8 & ]. Animal models are extremely useful for testing microbicide safety and efficacy, because unlike human trials, animals may be directly exposed to infectious doses of pathogenic viruses, resulting in very small numbers of animals required to significantly tackle key questions. In fact, sometimes, human clinical trials 'lie or exaggerate' as data are often contradictory or unclear. For example, the Carraguard microbicide study, which did not demonstrate efficacy in protection, still taught us much about human compliance and reporting. This study used gel applicators which had a groove that could be tested for the presence of vaginal mucus, which revealed that only 42% of the empty applicators had actually been used, despite self-reporting from the women stating that they used the applicator 96% of the time [17] .
More recently, other studies are showing noncompliance is a major issue with microbicides efficacy in humans. Although a study of oral tenofovir for PrEP in one African cohort of men and women showed significant protection from HIV infection [44] , another large scale study of oral and topical tenofovir known as Vaginal and Oral Interventions to Control the Epidemic (VOICE) revealed no protection in women using tenofovir. However, more recent investigations revealed that in this study, fewer than 30% of young women were actually taking the pills, and even fewer were using the gels, which explained why no protection was reported in these women ( ]. For these, and other reasons (limited inability to collect adequate or repeated mucosal tissues) reliable and accurate safety and efficacy information is best obtained using animal models prior to very expensive human clinical trials. Further, as animal models can be challenged with 100% infectious doses of HIV or SHIV, and as compliance is not an issue, only a few animals are needed to determine significant levels of efficacy or safety of a candidate compound. Nonetheless, compliance and other social issues may explain why animal studies can demonstrate almost complete protection with a microbicide, whereas rates of protection may be much lower in human trials. In these aspects, well designed and conducted animal experiments are sometimes, at least scientifically, more informative than human clinical trials.
CONCLUSION
Despite the success with tenofovir as PrEP, continued screening and testing for a well tolerated, and inexpensive topical microbicide should continue, if not accelerate in relevant animal models. There are too many microbicide candidates currently in clinical development for all of them to be tested in human trials, and animal experiments, even in nonhuman primates, cost a fraction of what human trials require. As HIV transmission rates are so low, and as condoms or other behavior modifications are implemented in control arms of human trials, literally thousands of humans, and intense follow-up are required for an informative prevention trial. Therefore, standards or benchmarks need to be developed for advancing only the most promising candidates to such trials. Unfortunately, there is no current consensus as to what kinds of testing a microbicide candidate must pass before such decisions are made. However, with the repeated failures of the past, and now some successes that can be used as benchmarks for comparing safety and efficacy, perhaps we can design rational testing protocols that can rapidly screen promising candidates more quickly for advancement to human trials. Specifically, compounds with greater efficacy and less potential for toxicity should be pursued, such as fusion inhibitors, which do not permit infection of cells, and especially those that prevent downstream inflammatory signaling and recruitment of target cells to mucosal tissues. Further, as coitally dependent microbicides are demonstrating repeated failure in many human clinical trials, development and extensive pharmacokinetic and pharmacodynamics studies of tissue penetration, distribution, and persistence of microbicide candidates formulated in sustained delivery devices appears to be the most rational approach for HIV microbicide development, and these data can be readily obtained in existing animal models. Now that we have partially effective compounds demonstrated in human trials, this may help set the bar for comparative animal and human studies o safety and efficacy. Now that animal models are finally being validated as predictive of success in human trials, we hope that expansion, refinement and standardization of animal model testing will accelerate the development and advancement of an effective microbicide that can eventually make a difference in stemming the tide of the HIV epidemic.
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